Cancer panels use next generation sequencing (NGS) technology to target specific genes or mutations that have established relevancy to a particular cancer phenotype. NGS facilitates sequencing of large genomic regions, high numbers of genes, and/or high numbers of samples in a single, efficient and cost-effective assay. In addition, NGS provides significantly higher sensitivity than traditional techniques, which permits the discovery of rare somatic mutations, many of which have been identified as important cancer drivers.
Azenta offers several cancer panels to provide a complete solution from experimental design to advanced bioinformatics analysis. Each panel can be combined with any of our genomics, transcriptomics, proteomics, and epigenomics services for a multiomics approach, providing crucial insights into human cancer profiles and defining patterns that would have remained unseen and incomplete with just a single assay.
||Azenta Pan-Cancer Panel||GENEWIZ OncoGxOneTM
Discovery Cancer Panels
Amplicon Cancer Panel
|Sequencing Platform||Illumina MiSeq or HiSeq||Illumina MiSeq or HiSeq||Illumina MiSeq|
|Cancer Types Assayed||Single gene panel assay for multiple cancer types
||19 distinct gene panels, each assays a specific cancer (organ) type||Single gene panel assays multiple cancer types|
|Genes Covered||634||≈150 - 400||48|
|Genomic Variation Detection||
|Target Regions||≈ 2 Mb, consisting of exons and targeted promoter regions||≈ 2 - 5.4 Mb, consisting of all exons, UTRs, and relevant intron regions||≈35 Kb, consisting of mutational hot spots|
|Average Depth||>100x*||> 100x*||> 100x*|
|Target Enrichment||Twist Targeted Enrichment||Agilent SureSelect Targeted Enrichment||Illumina Targeted Amplicon Sequencing|
|DNA Input||> 100 ng||> 100 ng||> 250 ng|
Developing immunotherapies for cancer can be difficult due to the variation of immune response from patient to patient. In this webinar, Dr. Litchfield from UCL Cancer Institute presents his team’s exploratory research using a multiomics approach to better understand the diversity of immune response to cancer and highlights their findings of an alternative source of a tumour-specific antigen in checkpoint inhibitor (CPI) response.
Azenta is a certified service provider for Illumina NGS platforms and the PacBio Sequel. Please visit our NGS Platforms page for more information.